Kevin Deandrade, MD
Interventional Cardiology · Mobile, ALNPI 1174781017
Payments from drug & device makers
What this record shows
8 manufacturers reported payments, led by Penumbra, Inc. at 28.2% of the total. 2025 is the largest year on record at $2,381, 9.2 times the $258 reported in 2020. That places this record below the midpoint for interventional cardiology clinicians in AL, where the typical reported total is $6,630.
Across 64 payments — averaging $111.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$2K
- Edwards Lifesciences$2K
- Abbott$1K
- Medtronic$1K
- Abiomed$406
- Recor Medical Inc$118
- plus $205 from 2 others
Across 24 payments — averaging $9674.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$213K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$20K
What the payments were for
- Travel & lodging$3,54750%
- Food & beverage$3,61450%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 8 | $2,022 |
| Edwards Lifesciences | 17 | $1,752 |
| Abbott | 13 | $1,428 |
| Medtronic(2 entities) | 18 | $1,229 |
| Abiomed | 5 | $406 |
| Recor Medical Inc | 1 | $118 |
| Philips North America LLC | 1 | $117 |
| Cardiovascular Systems Inc. | 1 | $88 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,160 in reported general payments places this provider in the 50th percentile of 109 interventional cardiology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 282 | $279,959 |
| XareltoRivaroxaban | 245 | $245,883 |
| EntrestoSacubitril/Valsartan | 66 | $53,475 |
| Repatha SureclickEvolocumab | 73 | $53,041 |
| Metoprolol Succinate | 672 | $9,016 |
| BrilintaTicagrelor | 11 | $7,695 |
| Ranolazine ErRanolazine | 43 | $6,023 |
| Atorvastatin Calcium | 381 | $5,224 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 128 | $5,194 |
| Valsartan | 143 | $5,111 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 18 | $4,451 |
| ClopidogrelClopidogrel Bisulfate | 264 | $2,997 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 43 | $2,484 |
| Amlodipine Besylate | 410 | $2,220 |
| Cilostazol | 57 | $1,973 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Mobile
- John GallaMobile$82K
- Ahmed SubahiMobile$37K
- Mir HashimiMobile$24K
- Mohammed ElzeneiniMobile$23K
- Benjamin CitrinMobile$11K
- James GladdenMobile$9K
- Stanley ThorntonMobile$7K
- Michael MonsonMobile$7K
- Gary RoubinBirmingham$157K
- Michael ButlerHuntsville$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.